Samarth Kulkarni
Net Worth

Last updated:

What is Samarth Kulkarni net worth?

The estimated net worth of Dr. Samarth Kulkarni is at least $66,993,535 as of 24 Dec 2024. He owns shares worth $9,794,809 as insider, has earned $47,758,726 from insider trading and has received compensation worth at least $9,440,000 in CRISPR Therapeutics AG.

What is the salary of Samarth Kulkarni?

Dr. Samarth Kulkarni salary is $1,180,000 per year as Chief Executive Officer & Director in CRISPR Therapeutics AG.

How old is Samarth Kulkarni?

Dr. Samarth Kulkarni is 46 years old, born in 1979.

What stocks does Samarth Kulkarni currently own?

As insider, Dr. Samarth Kulkarni owns shares in one company:

Company Title Shares Price per share Total value
CRISPR Therapeutics AG (CRSP) Chief Executive Officer & Director 181,540 $53.95 $9,794,809

What does CRISPR Therapeutics AG do?

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRSP logo
CRSP
CRISPR Therapeutics AG
$53.95

Samarth Kulkarni insider trading

CRISPR Therapeutics AG

Dr. Samarth Kulkarni has made 73 insider trades between 2017-2024, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 80,000 units of CRSP stock on 3 Dec 2021. As of 24 Dec 2024 he still owns at least 181,540 units of CRSP stock.

Transaction Date Security Shares Price per share Total value Source
Option
Stock Option (Right to Buy) 13,751 $16.21 $222,904
Option
Common Shares 13,751 $16.21 $222,904
Sale
Common Shares 15,000 $55.1 $826,560
Sale
Common Shares 6,879 $56.27 $387,081
Sale
Common Shares 23,121 $55.43 $1,281,597
Sale
Common Shares 4,293 $46.28 $198,680
Option
Common Shares 8,333 N/A N/A
Option
Restricted Stock Units 8,333 N/A N/A
Sale
Common Shares 1,204 $60.4 $72,722
Option
Stock Option (Right to Buy) 19,582 $19.12 $374,408
Sale
Common Shares 18,378 $59.88 $1,100,511
Option
Common Shares 19,582 $19.12 $374,408
Option
Stock Option (Right to Buy) 20,000 $19.12 $382,400
Sale
Common Shares 10,613 $71.97 $763,807
Option
Common Shares 20,000 $19.12 $382,400
Sale
Common Shares 9,387 $73.06 $685,814
Sale
Common Shares 4,583 $74.44 $341,159
Option
Common Shares 9,000 N/A N/A
Option
Restricted Stock Units 9,000 N/A N/A
Sale
Common Shares 9,802 $78.26 $767,105
Option
Common Shares 19,250 N/A N/A
Option
Restricted Stock Units 19,250 N/A N/A
Sale
Common Shares 6,370 $79.67 $507,498
Option
Restricted Stock Units 13,250 N/A N/A
Option
Common Shares 13,250 N/A N/A
Sale
Common Shares 5,951 $81.04 $482,257
Option
Stock Option (Right to Buy) 20,000 $19.12 $382,400
Sale
Common Shares 12,949 $79.94 $1,035,091
Sale
Common Shares 1,100 $81.67 $89,832
Option
Common Shares 20,000 $19.12 $382,400
Option
Common Shares 50,000 $19.12 $956,000
Option
Stock Option (Right to Buy) 50,000 $19.12 $956,000
Sale
Common Shares 700 $61.1 $42,770
Sale
Common Shares 49,300 $60.5 $2,982,798
Sale
Common Shares 20,000 $62.5 $1,250,060
Option
Common Shares 20,000 $19.12 $382,400
Option
Stock Option (Right to Buy) 20,000 $19.12 $382,400
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Sale
Common Shares 2,400 $66.83 $160,402
Sale
Common Shares 5,999 $64.46 $386,684
Sale
Common Shares 7,301 $63.62 $464,453
Sale
Common Shares 9,300 $65.63 $610,359
Option
Common Shares 25,000 $19.12 $478,000
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Sale
Common Shares 4,393 $51.45 $226,020
Option
Common Shares 25,000 $19.12 $478,000
Sale
Common Shares 20,607 $50.5 $1,040,612
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Option
Common Shares 25,000 $19.12 $478,000
Sale
Common Shares 19,719 $44.37 $874,991
Sale
Common Shares 5,281 $44.78 $236,504
Option
Restricted Stock Units 9,000 N/A N/A
Option
Common Shares 9,000 N/A N/A
Option
Restricted Stock Units 11,833 N/A N/A
Option
Common Shares 11,833 N/A N/A
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Sale
Common Shares 10,180 $47.71 $485,708
Sale
Common Shares 1,100 $49.2 $54,119
Option
Common Shares 25,000 $19.12 $478,000
Sale
Common Shares 13,720 $48.57 $666,422
Option
Common Shares 13,250 N/A N/A
Option
Restricted Stock Units 13,250 N/A N/A
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Option
Common Shares 25,000 $19.12 $478,000
Sale
Common Shares 1,800 $50.6 $91,085
Sale
Common Shares 23,200 $51.54 $1,195,705
Sale
Common Shares 4,634 $41.46 $192,102
Sale
Common Shares 20,366 $40.81 $831,198
Option
Common Shares 25,000 $19.12 $478,000
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Option
Common Shares 58,233 $1.81 $105,402
Option
Stock Option (Right to Buy) 58,233 $1.81 $105,402
Option
Restricted Stock Units 40,000 N/A N/A
Option
Common Shares 40,000 N/A N/A
Sale
Common Shares 2,310 $55.4 $127,983
Option
Common Shares 25,000 $19.12 $478,000
Sale
Common Shares 17,118 $53.58 $917,251
Sale
Common Shares 5,572 $54.85 $305,596
Option
Stock Option (Right to Buy) 25,000 $19.12 $478,000
Option
Common Shares 5,418 $19.12 $103,592
Sale
Common Shares 7,188 $55.7 $400,336
Option
Stock Option (Right to Buy) 5,418 $19.12 $103,592
Option
Stock Option (Right to Buy) 19,582 $16.21 $317,424
Sale
Common Shares 11,312 $54.97 $621,775
Sale
Common Shares 4,000 $54.06 $216,256
Sale
Common Shares 2,500 $52.73 $131,830
Option
Common Shares 19,582 $16.21 $317,424
Option
Stock Option (Right to Buy) 25,000 $16.21 $405,250
Option
Common Shares 25,000 $16.21 $405,250
Sale
Common Shares 23,200 $64.58 $1,498,210
Sale
Common Shares 1,800 $64.97 $116,946
Option
Common Shares 25,000 $16.21 $405,250
Option
Stock Option (Right to Buy) 25,000 $16.21 $405,250
Sale
Common Shares 163 $67.64 $11,025
Sale
Common Shares 20,764 $66.98 $1,390,669
Sale
Common Shares 4,073 $66.14 $269,392
Option
Stock Option (Right to Buy) 8,333 $12.57 $104,746
Option
Common Shares 8,333 $12.57 $104,746
Option
Common Shares 16,667 $16.21 $270,172
Option
Stock Option (Right to Buy) 16,667 $16.21 $270,172
Sale
Common Shares 6,933 $75.64 $524,405
Sale
Common Shares 700 $76.37 $53,461
Sale
Common Shares 700 $77.79 $54,455
Sale
Common Shares 12,759 $75.73 $966,265
Sale
Common Shares 3,308 $76.29 $252,381
Sale
Common Shares 600 $77.97 $46,783
Option
Stock Option (Right to Buy) 25,000 $12.57 $314,250
Sale
Common Shares 20,260 $61.42 $1,244,450
Sale
Common Shares 4,740 $62.32 $295,406
Option
Common Shares 25,000 $12.57 $314,250
Option
Restricted Stock Units 11,834 N/A N/A
Option
Restricted Stock Units 9,000 N/A N/A
Option
Common Shares 9,000 N/A N/A
Option
Common Shares 11,834 N/A N/A
Option
Stock Option (Right to Buy) 17,750 $1.81 $32,128
Option
Common Shares 17,750 $1.81 $32,128
Option
Restricted Stock Units 80,000 N/A N/A
Option
Common Shares 80,000 N/A N/A
Option
Common Shares 33,000 $1.81 $59,730
Option
Stock Option (Right to Buy) 33,000 $1.81 $59,730
Option
Stock Option (Right to Buy) 28,500 $12.57 $358,245
Option
Common Stock 28,500 $12.57 $358,245
Sale
Common Stock 28,500 $128.73 $3,668,919
Option
Stock Option (Right to Buy) 1,500 $12.57 $18,855
Sale
Common Shares 1,500 $12.57 $18,855
Option
Common Shares 1,500 $12.57 $18,855
Sale
Common Shares 30,000 $126.59 $3,797,610
Option
Stock Option (Right to Buy) 30,000 $12.57 $377,100
Sale
Common Shares 30,000 $126.59 $3,797,610
Option
Common Shares 30,000 $12.57 $377,100
Option
Common Shares 11,833 N/A N/A
Option
Stock Option (Right to Buy) 20,000 N/A N/A
Option
Common Shares 20,000 N/A N/A
Sale
Common Shares 20,000 N/A N/A
Option
Common Shares 13,800 N/A N/A
Option
Stock Option (right to buy) 13,800 N/A N/A
Option
Stock Option (Right to Buy) 20,000 $1.81 $36,200
Option
Common Shares 20,000 $1.81 $36,200
Sale
Common Shares 20,000 $142.92 $2,858,320
Option
Stock Option (Right to Buy) 17,275 $1.81 $31,268
Option
Common Shares 17,275 $1.81 $31,268
Sale
Common Shares 17,275 $64.48 $1,113,892
Sale
Common Shares 10,693 $65.28 $698,039
Option
Stock Option (Right to Buy) 10,693 $65.28 $698,039
Option
Common Shares 10,693 $65.28 $698,039
Sale
Common Shares 4,307 $1.81 $7,796
Option
Common Shares 4,307 $1.81 $7,796
Option
Stock Option (Right to Buy) 4,307 $1.81 $7,796
Option
Stock Option (Right to Buy) 8,000 $1.81 $14,480
Option
Common Shares 8,000 $1.81 $14,480
Option
Common Shares 20,000 $1.81 $36,200
Sale
Common Shares 20,000 $1.81 $36,200
Option
Stock Option (Right to Buy) 20,000 $1.81 $36,200
Sale
Common Shares 20,000 $1.81 $36,200
Option
Stock Option (Right to Buy) 20,000 $1.81 $36,200
Option
Common Shares 20,000 $1.81 $36,200
Option
Common Shares 21,500 $1.81 $38,915
Option
Stock Options (Right to Buy) 21,500 $1.81 $38,915
Option
Common Shares 15,000 $1.81 $27,150
Sale
Common Shares 15,000 $68.78 $1,031,700
Option
Employee Stock Option (right to buy) 15,000 $1.81 $27,150
Option
Common Shares 15,000 $1.81 $27,150
Option
Employee Stock Option (right to buy) 15,000 $1.81 $27,150
Sale
Common Shares 4,000 $20 $80,000
Sale
Common Shares 23,154 $20.09 $465,164
Option
Common Shares 2,206 $16.78 $37,023
Option
Stock Options (Right to Buy) 2,206 $16.78 $37,023
Sale
Common Shares 2,206 $16.78 $37,023
Sale
Common Shares 3,275 $1.81 $5,928
Option
Common Shares 3,275 $1.81 $5,928
Option
Stock Options (Right to Buy) 3,275 $1.81 $5,928
Option
Common Shares 5,115 $16.87 $86,290
Option
Stock Options (Right to Buy) 5,115 $16.87 $86,290
Sale
Common Shares 5,115 $16.87 $86,290
Sale
Common Shares 3,500 $16.46 $57,621
Option
Common Shares 3,500 $16.46 $57,621
Option
Stock Options (Right to Buy) 3,500 $16.46 $57,621
Sale
Common Shares 3,000 $1.81 $5,430
Option
Common Shares 3,000 $1.81 $5,430
Option
Stock Options (Right to Buy) 3,000 $1.81 $5,430
Option
Stock Options (Right to Buy) 2,800 $17.37 $48,622
Option
Common Shares 2,800 $17.37 $48,622
Sale
Common Shares 2,800 $17.37 $48,622
Option
Common Shares 7,258 $1.81 $13,137
Option
Stock Options (Right to Buy) 7,258 $1.81 $13,137
Sale
Common Shares 7,258 $18.04 $130,927

CRISPR Therapeutics AG key executives

CRISPR Therapeutics AG executives and other stock owners filed with the SEC: